论文部分内容阅读
加味左金丸由黄连、吴茱萸、木香组成,本文将原处方制备成胶囊剂后,进行了药效学和含量测定的研究,检验制备工艺对药效和主要成分含量的影响。胶囊剂对大鼠应激性溃疡发生指数抑制率为66.86％,与雷尼替丁类似。对盐酸—乙醇所致大鼠胃粘膜损伤的溃疡指数抑制率为99.38％。以上药效有剂量依赖性。实验结果与加味左金丸汤剂的结果(已发表资料)基本一致。根据《药典》的技术方法,测定胶囊剂中小檗碱的含量,结果为6.6％。参考《药典》对类似处方制剂的规定(香连丸小檗碱含量不得少于6.0％,左金丸不得少于5.6％),提示胶囊剂的小檗碱含量符合要求,可作为质量标准控制的参考。
The modified Zuojin Pill consists of Coptis chinensis, Euphorbiaceae, and woody notes. After the capsules were prepared in the original prescription, the pharmacodynamics and content determination studies were conducted to examine the effect of the preparation process on the efficacy and the content of the main components. The capsule inhibition rate of stress ulcer in rats was 66.86%, similar to that of ranitidine. The inhibitory rate of ulcer index in rat gastric mucosal damage induced by hydrochloric acid-ethanol was 99.38%. The above efficacy is dose-dependent. The experimental results are basically consistent with the results of the Modified Zuojin Pill Decoction (published data). According to the “Pharmacopoeia” technical method, the content of berberine in the capsule was determined and the result was 6.6%. Reference to the “Pharmacopoeia” provisions for similar formulations (berberine berberine content should not be less than 6.0%, Zuojin Pill not less than 5.6%), suggesting that the capsule berberine content meets the requirements, can be used as a quality standard control reference.